A case of disodium cromoglycate-induced bronchoconstriction in aspirin-sensitive asthma.
- Author:
Chein Soo HONG
;
Jung Won PARK
;
Cheol Woo KIM
;
Young Hwa CHOI
- Publication Type:Case Report
- MeSH:
Asthma*;
Asthma, Aspirin-Induced;
Bronchial Spasm;
Bronchoconstriction*;
Capsules;
Humans;
Inhalation;
Mast Cells;
Metered Dose Inhalers;
Mouth;
Nebulizers and Vaporizers;
Occupations;
Peak Expiratory Flow Rate;
Pharynx;
Thorax
- From:Korean Journal of Allergy
1997;17(3):325-331
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Disodium cromoglycate(DSCG) has been widely used in the treatment of bronchial asthma and has become the prophylactic drug of choice in patients with mild-to-moderate asthma, because it has anti-allergic, anti-inflammatory and mast cell stabilizing properties. DSCG has been considered one of the safest medications among drugs for asthma treatment. The most common side effects are irritation of throat and dry mouth. Bronchospasm and chest tightness have been reported, but they were usually experienced by patients using spinhaler powdered capsules rather than metered dose inhalers (MDI). In this report, we presented a case of recurrent DSCG-induced bronchoconstriction with brief review of the literature. He had had an aspirin-induced asthma and had been well controlled with steroid inhalers and DSCG-MDI. After aspirin-bronchopro vocation test, he complained of chest discomfort and tightness immediately after inhaling DSCG-MDI. On serial monitoring of peak expiratory flow rate (PEER), there was a significant decline of PEER after two puffs inhalation of DSCG-MDI. Thus we performed DSCG-inhalation broncho provocation test with the nebulizer solution, which was pure DSCG without any addition of ingradients or propellants. This produced an early asthmatic reaction with more than 40% decline of FEV,. He was diagnosed as DSCG-induced bronchoconstriction and his clinical conditions were improved after avoidance of DSCG-MDI.
